Objective: Endovascular stent-grafting provides an alternative treatment option for high-risk patients with ascending aortic disease. The feasibility of this approach has been demonstrated before. We assess the updated experience with ascending thoracic endovascular aortic repair and propose a modification of the landing zone classification based on the outcomes.
Perspective
The modified zone zero classification is useful for characterizing the extent of ascending aortic pathology and assessing the prognosis. Location of the defect varies by pathology, and the presence of 0A disease predicts worse outcomes. The design of endovascular devices should be tailored to aortic pathology and zone characteristics.
See Editorial Commentary page 1390.
See Editorial page 1358. The conventional treatment of proximal aortic aneurysm or dissection is open repair, but some patients are too high risk for this approach and may benefit from a less-invasive alternative with thoracic endovascular aortic repair (TEVAR). 1 Several studies have reported the feasibility and safety of stent-grafting as a purely endovascular procedure or as part of a hybrid approach for treating ascending and arch aortic pathology, but details about patient selection and long-term outcomes are less well known. [1] [2] [3] Currently, there are no commercially available endovascular devices specifically designed to treat the ascending aorta, and only a small number of studies have described outcomes with the endovascular approach to ascending aortic disease with commercially available devices used offlabel or with early-generation investigational devices. [4] [5] [6] [7] Compared with TEVAR of the descending thoracic aorta, endovascular therapy for the ascending aorta is challenged by more complex pathology, volatile hemodynamics, and variable anatomy within a concentrated anatomic space. However, this entire proximal anatomic segment is currently rather vaguely referred to as ''zone zero.'' 8 Several device manufacturers are actively pursuing research and development of ascending stent-graft systems. 9 With the prominence of transcatheter aortic valve replacement, the prospect of combining the 2 technologies is also a realistic consideration. 10 We recently published our experience with endovascular procedures to treat disease involving the ascending aorta in 22 high-risk patients, and several others have described small experiences. 1 To date, 39 patients have been treated with this approach. In this article, the outcomes from this experience are updated, and a modification to the landing zone classification is proposed on the basis of this analysis ( Figure 1 ).
PATIENTS AND METHODS Updated Experience With Ascending Stent-Grafting
From 2006 to November 2016, 39 patients underwent endovascular supracoronary ascending aortic repair at Cleveland Clinic. Presentation and indications for repair included acute type A dissection (n ¼ 12, 31%), acute intramural hematoma (IMH) (n ¼ 2, 5%), pseudoaneurysm (n ¼ 22, 56%), and chronic dissection with false lumen perfusion from a distal suture line entry tear after ascending aortic replacement (n ¼ 3, 8%). All patients were considered high risk for conventional open repair at the time of presentation. The Cleveland Clinic Institutional Review Board approved the study with patient consent waived. Table 1 outlines the distribution of comorbidities according to underlying aortic pathology at presentation. Of note, the underlying comorbidities were similar in the 3 groups, except that coronary artery disease (P ¼ .014) and history of cardiac surgery (P < .001) were significantly higher in patients with pseudoaneurysm.
Operative Details and Technique
Stent-grafts were used in 36 patients (95%), atrial septal occluder devices were used in 2 patients, and coil embolization was used in 1 patient. Of the 2 patients in whom an atrial septal occluder device was used to close the defect, 1 presented with pseudoaneurysm after previous aortic root replacement and a fistula from the posterior wall of the mid-aorta to the right main pulmonary artery. The presence of a small mechanical aortic valve prevented crossing with a stent-graft device. Both pulmonary artery and aortic defects were plugged with septal closure devices and the aortic one was reinforced by a balloon-expandable stent in the ascending aorta. In the other patient, the pseudoaneurysm origin was in close vicinity to both a critically important coronary bypass graft and the brachiocephalic artery without enough room for the commercially available stent-grafts. In 1 patient an endovascular occlusion of a pseudoaneurysm was attempted by embolization, but was not successful and an open repair was performed instead.
All procedures were done under general anesthesia with heparin for anticoagulation. Device delivery was transfemoral (n ¼ 22, 56%), transapical (n ¼ 8, 22%), or through the axillary artery (n ¼ 9, 23%). Transfemoral delivery was performed over a stiff wire with access across the aortic valve (Video 1). Transapical delivery used through-and-through wire access to the left subclavian artery, and axillary delivery was performed through a 10-mm surgical graft. In 2 patients, the device was deployed on full cardiopulmonary bypass. One of these had a left ventricular ejection fraction of 10%, and the other had severe right heart failure with wide open tricuspid regurgitation that was repaired surgically simultaneously through a full sternotomy on the beating heart and the ascending pseudoaneurysm was stented via transfemoral access. In all others, rapid ventricular pacing during deployment reduced displacement forces. Transesophageal echocardiography and fluoroscopy guided positioning. Completion angiogram was performed to assess Abbreviations and Acronyms IMH ¼ intramural hematoma TEVAR ¼ thoracic endovascular aortic repair Scanning this QR code will take you to a supplemental video for this article.
coronary and arch vessel patency, and to rule out endoleak. All patients were transferred from the hybrid operating room to the intensive care unit.
More than 1 stent-graft device was used in 18 patients (50%). The ascending aorta was anatomically divided into 3 segments to describe the proximal-most extent of disease and device positioning. Results of this classification are shown in Table 2 .
Definitions, Follow-up, and Statistics
Operative mortality is defined as death occurring within 30 days of the procedure or during hospitalization. Stroke was defined as neurologic deficit lasting greater than 24 hours confirmed by cross-sectional imaging of the brain or documentation by a neurologist. Renal failure was defined as the need for hemodialysis, and respiratory failure was defined as the need for reintubation or tracheostomy postoperatively. Computed tomography was performed before discharge, during outpatient follow-up at 3 months, and then annually unless otherwise indicated. Median follow-up was 13.4 (1-100) months.
Descriptive statistical analyses are used to present variables for the study. Continuous variables are presented as median or mean AE standard deviation, and categoric variables are presented as percentages. Time to event analysis was performed using the multivariable Cox proportional hazard regression. Tests for proportional hazard assumption were performed using the scaled Schoenfeld residuals, which indicated that the model assumptions were not violated (P ¼ .206). Long-term survival was estimated using the Kaplan-Meier method, and the log-rank test was used to assess significance.
RESULTS

Disease Extent According to Zone
In the first group of patients with acute type A dissection or IMH, the aortic pathology extended proximally to zone 0A in 10 (71%) and 0B in 4 (29%). All patients in the group who were treated for pseudoaneurysm had a previous cardiac operation, and 59% had a surgical graft from previous ascending aortic replacement. The location of the defect in these patients was at 0B in 11 patients (50%) and more distally 0C in 10 patients (45%). In 1 patient, although the defect was more distal, the pseudoaneurysm was large and extended proximally as far as zone 0A. In the third group of patients with chronic dissection and persistent proximal flow into the false lumen, the defect was located at the distal suture line in 0C in all 3 patients.
Proximal Landing Zone Location of Thoracic Endovascular Aortic Repair in Zone 0
In 4 patients, the proximal landing zone for TEVAR partially extended into 0A; in 3 of these patients the indication was acute type A dissection and 1 patient had IMH. These included 1 with partial coverage of the left main coronary requiring open conversion and 1 who had a previous transcatheter aortic valve in place. In all remaining cases of acute type A dissection, pseudoaneurysm, and chronic dissection, the proximal landing zone for TEVAR was in zone 0B. The distal landing zone was 0C in most patents except for 1 who underwent additional stent-grafting of the arch and descending aorta with a branched device (Figure 2 ).
Predictors of Mortality
After adjusting for baseline patient characteristics, surgical indication, and comorbidities, multivariable time to event analysis using Cox regression model showed that older age (P ¼ .026) and aortic pathology extending into zone 0A (P ¼ .020) were independent predictors of mortality ( Table 2 ). The presence of acute type A dissection (P ¼ .59) and proximity of landing zone (P ¼ .291) were not significantly associated with overall death. Table 3 provides the summary of aortic pathology by zone in patients who died.
Early Events
Four patients (10%) required early conversion to open repair: 1 for a retained delivery system, 1 for left main coronary occlusion, 1 for acute aortic insufficiency due to displacement of a mechanical valve leaflet, and 1 for whom embolization of the pseudoaneurysm was not successful. Of the 4 patients who underwent early conversion to open repair, 3 are still alive during late follow-up. There were 5 (13%) hospital deaths; 1 was intraoperative. All 5 patients underwent emergency repair of acute type A dissection. One refused blood transfusions for religious reasons and died on postoperative day 4 due to rupture and tamponade. Another had dissected a chronic ascending aneurysm that eroded into the left atrium, and he bled from the left atrium after ascending stent-grafting resulted in tamponade and intraoperative death. Two patients died of multiorgan failure postoperatively, including 1 with partial occlusion of the left coronary artery that required conversion to open repair. The other patient had progressive cardiopulmonary collapse and died of cardiac arrest on postoperative day 5. The patient who required open conversion for a retained delivery system tolerated the repair, but required later reoperation for an apical pseudoaneurysm. This patient is still alive and doing well 5 years later. The other patient who required conversion for acute aortic insufficiency also tolerated the redo root and ascending and arch repair but required a right leg fasciotomy for compartment syndrome.
Four patients (10%) had stroke (1 delayed by 2 weeks), 2 patients (5%) had myocardial infarction, 2 patients (5%) required tracheostomy for respiratory failure, and 2 patients (5%) developed renal failure requiring dialysis.
Long-term Survival
Overall, the estimated survival at 30 days, 1 year, and 5 years was 81%, 74%, and 64%, respectively (Figure 3 ). Among patients who underwent ascending TEVAR for pseudoaneurysm, the survival at 30 days, 1 year, and 5 years was 100%, 90%, and 68%, respectively, versus in patients with acute type A dissection/IMH, in whom the survival was 57%, 41%, and 41%, respectively (P ¼ .0057). Survival in patients with zone 0A pathology was significantly worse compared with those with 0B or 0C disease. At 30 days, 1 year, and 5 years, the survival was 55%, 33%, and 33% in patients with 0A disease versus 92%, 88%, and 75%, respectively, in patients with 0B or 0C disease (P ¼ .0018). There were 8 late deaths: 1 from lung cancer, 1 from pneumonia, and 1 from rupture of an intracranial aneurysm. One patient was a 91-year-old who had a stroke and was discharged to a nursing facility, where he died. The exact cause is unknown in 4 patients.
Late Reinterventions
One patient had distal migration of the stent-graft into the arch found incidentally during 6-month follow-up computed tomography. He had no symptoms, and the pseudoaneurysm completely resolved. At the time of endovascular repair, the patient was acutely ill but had since recovered, and the migrated device was extracted electively via an open approach. The other late reoperation was for a ventricular apex pseudoaneurysm caused by wire perforation.
In 2 other patients, open reoperations were planned as part of a staged approach. Emergency TEVAR was performed first in both patients who were too sick at presentation but later recovered to become candidates for open repair. One had acute dissection and rupture 2 months after mitral repair and coronary bypass grafting complicated by myocardial infarction requiring coronary stenting. The rupture was successfully treated by stent-grafting, and the residual dissection and aneurysm were treated 4 months later when clopidogrel could be safely stopped. The other patient presented with hemoptysis, respiratory failure, and cardiogenic shock due to high-output fistula. The fistula was treated endovascularly, the patient's condition was stabilized, and he was safely taken for redo open repair 6 days later.
Endovascular Reinterventions
One patient was treated with TEVAR extension for distal type 1 endoleak, and it resolved. Two patients underwent coil embolization of the pseudoaneurysm for endoleak. There were 5 other type 1 endoleaks. One patient had the planned conversion described in the previous paragraph, 1 patient without aneurysm resolved slowly over 2 years, 2 patients refused further treatment, and 1 patient is being monitored expectantly.
Freedom From Reintervention
At 1 month and 1, 3, and 5 years, the freedom from reintervention was 85%, 77%, 77%, and 68%, respectively. There was no significant difference in groups by indication (P ¼ .49) (Figure 3, C) . Six (18%) of 34 survivors required late reinterventions (4 open, 2 endovascular). One 88-year-old woman and one 85-yearold woman have persistent distal endoleak after stent-grafting for acute type A dissection but refuse any further therapy.
DISCUSSION Zone Zero Stent-Grafting for Arch Disease
Hybrid aortic repair combining open and endovascular techniques can be performed in multiple ways and may be classified by mechanical circulatory support and timing. Much of what has been written about zone zero stent-grafting has involved type 1 or type 2 hybrid operations where the arch vessels are debranched, or transposed, to a more proximal portion of the native ascending aorta (type 1 hybrid arch repair) or an ascending surgical graft (type 2 hybrid arch repair) with subsequent stent-grafting from the ascending aorta segment through the native arch and descending segments. 3 Results from small single-center series have been reasonable for this approach, but retrograde dissections have been reported to occur in as many as 24% of patients undergoing type 1 hybrid repair because the ascending aorta is often diseased. 10 Although placing the stent-graft into a surgical graft can address the problem of retrograde dissection, type 1 endoleaks are too common in both type 1 and type 2 hybrid repairs. Previously placed surgical grafts are often too short to accommodate a debranching source and provide a landing zone for fixation and seal of the stent-graft. A type 3 hybrid repair combining open circulatory arrest and endovascular devices can address the shortcomings presented by both type 1 and type 2 repairs. 10, 14, 15 However, all of these hybrid techniques are directed at disease primarily involving the arch and descending aorta.
Zone Zero Stent-Grafting for Ascending Aortic Disease
For patients with disease predominantly involving the ascending aorta, open surgical replacement has been shown to be safe for the majority of patients, including those requiring reoperations and multi-component operations. 11 However, there is an underappreciated need to provide alternative therapy for patients considered high risk for open repair. 12, 13 Several centers have used stent-graft devices to treat ascending aortic disease demonstrating feasibility for select patients using both off-label application of commercially available devices and with very early versions of investigational devices. [3] [4] [5] [6] [7] These early experiences have demonstrated some important challenges to ascending aortic endovascular repair that can be categorized as patient related or procedure related.
Patient-related challenges to ascending TEVAR include issues with the specific anatomy and morphology of the ascending aorta. Although we typically use straight tubular grafts to perform ascending replacement, the native segment is different from a straight tube. The posterior wall and lesser curve of the aorta are shorter than the greater curve and anterior walls (Figure 4) . In our earlier analysis of computed tomography of patients with an ascending stent-graft, we found that the greater curve is more than 30% longer than the lesser curve along the length of the ascending aorta. 3 In a more recent imaging analysis of computed tomography scans from a population of patients deemed inoperable for acute type A dissection, we found a similar difference in length measurements. 12 The population of patients deemed inoperable for acute type A dissection presents an unmet need. In our experience, 7.7% of patients with type A dissection were not offered an operation. In the International Registry of Aortic Dissection (IRAD) experience, they found that more than 20% of patients with type A dissection were deemed inoperable. 13 A fundamental principle for successful endovascular treatment of these patients is the need to cover the proximal entry tear. Identifying this lesion on preoperative imaging was possible in most patients but still represents an important challenge going forward. For many of these patients, the reasons for inoperability may not be prohibitive if a stent-graft was available as a less morbid mechanical treatment option that allowed us to cover the entire ascending aortic segment.
This experience also introduces the potential role of this technology as an adjunct to definitive repair. We demonstrated in our experience that most patients who required open conversion (3/4 early and 5/6 overall) are late survivors.
The collective experience of ascending stent-grafting has brought to light many of the important details about the procedure and shortcomings of the current technology. Before designing the ideal device, it will be helpful to improve our understanding of the boundary conditions for these devices. Studies are ongoing to better characterize the elasticity and compliance, load testing, and histology of the ascending aorta in the normal, aneurysmal, and acutely dissected states. This knowledge will help to guide the development of better site-specific and disease-specific devices.
The next-generation ascending stent-graft device needs to be highly conformable and elastic with adequate strength of fixation in what is a hostile environment. The device likely needs to be curved like the ascending aorta. It should have a relatively flush edge proximally so that it does not impose on the origins of the coronaries or the commissures of the aortic valve despite the need to abut them. As we learn more about the endovascular treatment of ascending disease, we will better understand the need for branched devices to accommodate the brachiocephalic and other arch branch vessels so that distal seal and fixation are achieved.
The novel delivery systems will need to be exceedingly precise to allow for controlled deployment at the sinotubular junction in a coaxial plane. This may require a repositionable system that is steerable. The tip of the delivery system needs to be short because of the proximity to the aortic valve. The least-invasive delivery options are retrograde, but a system that allows for antegrade delivery from the left ventricular apex may be considered.
Study Limitations
This is a retrospective analysis. Imaging data were not available in all patients with acute type A dissection. The study population consisted of a heterogeneous mix of patients with diverse presentation and aortic pathology.
Finally, because of a small sample size, the scope of the analysis was limited but still offers important insight into the development of this novel treatment.
Proposed New Classification for Zone Zero
In the current landing zone classification system, any portion of the aorta proximal to the left common carotid artery is considered zone zero. 8 In the latest analysis of our experience at the Cleveland Clinic in performing ascending stent-grafting, we have found that there is an important difference in procedural difficulty and early and intermediate outcomes based on a more granular view of the proximal landing zone. In this modified classification system, we further delineated zone zero into 3 segments. Zone 0A constitutes the aortic root and is defined proximally by the left ventricular outflow tract and distally by the distal edge of the coronary ostia. Zone 0B constitutes the proximal half of the ascending aorta and is defined as the region between the distal coronary ostia and the right main pulmonary artery, and zone 0C is the distal half of the ascending aorta extending from the right main pulmonary artery and including the brachiocephalic trunk (Figure 1 ).
Our analysis of both early and late outcomes based on this more precise modified zone zero classification system validates its use as both a descriptive and prognostic tool. It was not surprising to find that all of the early deaths in this experience were in patients with acute dissections, but the risk was particularly high in those with acute dissections involving the root (one third has zone 0B disease). The time to event analysis included all deaths, and the multivariable analysis of this outcome demonstrated that extent zone 0A disease independently predicted mortality irrespective of the underlying aortic pathology.
CONCLUSIONS
Some of these associations could be related to the shortcomings of the current technology that are particularly ill-suited for the proximal most segment of the aorta. As our understanding of the disease and the technology to treat it evolves, we can anticipate having both site-and disease-specific devices for endovascular repair of the proximal aorta. Now is the time to expand the zone-based classification system to better describe the proximal aorta so that we can gather more detailed data to facilitate these advances.
